Abstract
Introduction Rheumatoid Arthritis (RA) and autoimmune thyroid disease (AITD) are the two most prevalent autoimmune diseases that can coexist due to their similar pathogenesis. Considering the potential effect of AITD on the severity of RA disease, this study aimed to determine the association between thyroid dysfunction, anti-thyroid peroxidase (anti-TPO) positivity, AITD, and RA disease severity in the Iranian population.
Materials and methods Three hundred and fifty RA patients who presented to Shahid Beheshti tertiary care center, Qom, Iran, were included in this cross-sectional study. The data were collected through the patients’ medical records, interviews, physical examinations, and laboratory investigations. The disease activity score in 28 joints for RA with ESR (DAS-28-ESR) was used to divide patients into three groups, remission (DAS-28-ESR ⍰2.6), mild-to-moderate (2.6 < DAS-28-ESR ⍰5.1), and severe disease activity (DAS-28-ESR > 5.1).
Results Using the method explained beforehand, 111, 96, 138 patients were sorted into remission, mild-to-moderate, and severe disease activity groups, respectively. Anti-TPO antibody positivity was 2.93 times more prevalent among patients with higher severity of disease than in remission (OR: 2.93; P-value < 0.001). Patients suffering from a more severe form of the disease were almost 2.7 times more probable to have AITD (OR = 2.71; P-value < 0.001) and 82% more likely to have thyroid dysfunction than the patients in remission (OR = 1.82; P-value = 0.006).
Conclusions It was demonstrated that thyroid dysfunction, anti-TPO antibody positivity, and AITD were significantly more common among RA patients with higher disease activity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the Declaration of Helsinki and the protocol approved by the ethics committee of Qom University of Medical Sciences (IR.MUQ.REC.1400.042).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated and analyzed during the current study are not publicly available due to restrictions in ethical and data management approvals. Still, they are available from the corresponding authors upon reasonable request.
